Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Nemtabrutinib FMF1 in Healthy Males
NCT06772805Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nemtabrutinib in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM) (2 arms), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity at 2 weeks. Started Jul 2023; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT06772805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772805.